查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1445542

血管生成抑制劑和促進劑市場評估：按產品、應用、最終用戶和地區劃分的機會和預測（2017-2031）

Angiogenesis Inhibitors and Stimulators Market Assessment, By Product, By Application, By End-user By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 231 Pages | 商品交期: 3-5個工作天內

價格

2024-2031年預測期內，全球血管生成抑制劑和促進劑市場規模將以10.01%的複合年增長率增長，從2023年的251.5億美元增長到2031年的539億美元，預計將增長至5000萬美元。

各種類型的癌症（包括肺癌、乳癌和攝護腺癌）的負擔日益增加，導致對治療方法開發的投資增加。 據美國癌症協會稱，2023 年僅美國就將報告 1,958,310 例新癌症病例和 609,820 例癌症相關死亡。 此外，人們對使用血管生成抑制劑和促進劑治療各種疾病的認識的提高和技術的進步也支持了市場的成長。 技術進步正在徹底改變血管生成抑制劑和促進劑的開發。 新的藥物傳輸系統，包括脂質體和奈米顆粒，正在減少副作用並提高藥物療效。 此外，組織工程技術和生物材料的整合正在支持調節血管生成新方法的開發。

癌症盛行率的增加支持市場成長

世界各地各種類型癌症的盛行率不斷增加，增加了對血管生成抑制劑的需求。 這些抑制劑透過抑制新血管的形成來阻止腫瘤生長並穩定腫瘤。 根據約翰霍普金斯大學醫學發表的論文，血管生成抑制劑貝伐單抗已被證明可有效治療多種類型的癌症，包括轉移性腎細胞癌、大腸直腸癌、神經內分泌腫瘤、非小細胞肺癌、膠質母細胞瘤和肝癌癌症。它可用於癌症治療。

重視研發活動

研發活動有許多好處，包括支持創新、促進新產品和服務的開發以及提高現有產品的有效性。 這些活動提高了標靶治療的準確性和有效性，並使研究人員能夠減少其產品現有的限制。 各個參與公司和研究機構都致力於研發活動，以加速治療有效產品的開發，並了解現有治療方法與其他治療方法相結合的有效性。 武田藥品工業株式會社發起了一項幹預措施，旨在評估魯沙佐米聯合地塞米松和來那度胺對先前接受硼替佐米誘導治療的患者在2 年內對多發性骨髓瘤進展的影響。該試驗的第4 期試驗目前正在進行中。 本研究正在調查接受地塞米松和來那度胺合併魯沙佐米全口服合併治療的參與者的安全性和有效性。

本報告調查了全球血管生成抑制劑和促進劑市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構和市場成長。影響因素分析、案例研究、競爭優勢分析主要公司的概況和概況。

目錄

第 1 章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第 4 章全球血管新生抑制劑與促進劑市場展望

  • 市場規模/預測
  • 按產品
    • 血管新生管形成測定
    • 微流控
    • 內皮黏附
    • 侵襲和遷移測定
  • 依用途
    • 體外血管生成
    • 體內血管生成
  • 最終用戶
    • 醫院
    • 診所
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 各公司的市佔率

第 5 章全球血管新生抑制劑與促進劑市場展望：按地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 6 章市場映射

  • 按產品
  • 依用途
  • 按最終用戶
  • 按地區

第 7 章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 生長抑制因素（問題、限制因素）

第 9 章監理架構與創新

  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第 10 章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（5 家參與公司）
  • 專利分析（如果適用）

第 11 章價格分析

第 12 章案例研究

第 13 章主要公司展望

  • Pfizer, Inc.
  • Novartis AG
  • Abbott Laboratories
  • F. Hoffmann-La Roche, Ltd.
  • Johns Hopkins Medicine
  • Bristol-Myers Squibb Company
  • Eyetech, Inc.
  • Bayer AG
  • Takeda Pharmaceutical Company Ltd.
  • Sun Pharmaceutical Industries Ltd.

第 14 章策略建議

第 15 章關於我們公司/免責聲明

Product Code: MX11091

Global angiogenesis inhibitors and stimulators market is projected to witness a CAGR of 10.01% during the forecast period 2024-2031, growing from USD 25.15 billion in 2023 to USD 53.95 billion in 2031. The growing burden of different types of cancers, including lung, breast, and prostate cancer, is increasing investments in developing different therapeutic treatments. As per the American Cancer Society, in 2023, 1,958,310 new cancer cases and 609,820 cancer related deaths occurred in the United States alone. Furthermore, the growing awareness about the utilization of angiogenesis inhibitors and stimulators for the treatment of various conditions and technological advancements are supporting the market growth. Advancements in technology are revolutionizing the development of angiogenesis stimulators and inhibitors. Novel drug delivery systems, including liposomes and nanoparticles, reduce side effects and improve drug efficacy. Additionally, tissue engineering techniques and the integration of biomaterials are supporting the development of novel avenues for modulation of angiogenesis.

The growth of medical tourism in different regions across the globe is also expected to augment the growth of the market in the coming years. Such factors encourage different governments and research organizations to support novel product development and research activities. Key players and market and research institutions are heavily engaged in research and development activities to develop novel products that offer enhanced therapeutic efficacy. For instance, the National Cancer Institute of Naples are in the phase 4 of a study that is being conducted to explore the role of biological and clinical factors in patients with ovarian cancer who are receiving paclitaxel and carboplatin with bevacizumab.

Increasing Prevalence of Cancer Supports Market Growth

The growing prevalence of different types of cancer in various regions across the globe is propelling the requirement for angiogenesis inhibitors. These inhibitors prevent the growth of the tumor and stabilize it by blocking the formation of new blood vessels. According to an article published by Johns Hopkins Medicine, Bevacizumab, an angiogenesis inhibitor medicine, aids in the treatment of different types of cancer, including metastatic renal cell cancer, colorectal cancer, neuroendocrine tumors, non-small cell lung cancer, glioblastoma, and liver carcinoma.

Due to the central role of the VEGF/VEGFR signaling axis in cancer angiogenesis, various anti-angiogenic medicines, including VEGFR tyrosine kinase inhibitors (TKIs), anti-VEGF antibodies, and anti-VEGFR antibodies, have been authorized for different types of cancer. Researchers Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, et al. discovered that treatment with Bevacizumab and hypoxia-inducible factor 1(HIF-1) inhibitors have a greater anti-cancer impact as opposed to therapy with Bevacizumab only in glioma xenografts. Furthermore, various market players are also investing in evaluating the safety and efficacy of Bevacizumab, including Hoffmann-La Roche, which is conducting a stage four clinical trial in an interventional study of Bevacizumab in patients suffering from metastatic or advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Increasing Emphasis on Research and Development Activities

Research and development activities offer various benefits, including supporting innovation, facilitating the development of novel products and services, and enhancing the efficacy of existing products. These activities enhance the accuracy and efficacy of targeted therapies and allow researchers to reduce the existing limitations of the product. Various market players and research organizations are heavily engaged in research and development activities to promote the development of products that provide enhanced therapeutic efficacy and understand the effects of existing therapies in combination with others. For instance, Takeda Pharmaceuticals is in phase 4 of their interventional study that aims to evaluate the effect of lxazomib in combination with dexamethasone and lenalidomide on the progression of multiple myeloma in two years in patients who had previously received a bortezomib-based induction regimen. The study will look at the safety and effectiveness of participants who are taking the all-oral combination of dexamethasone and lenalidomide with lxazomib.

North America Dominates Angiogenesis Inhibitors and Stimulators Market

North America is expected to account for a significant share of the market owing to the strong presence of various leading market players and the rapid expansion of the biotechnology and pharmaceutical industry in the region. The large patient base and expansion of the treatment seeking population in North America are further bolstering the market growth.

Due to the increasing prevalence of various diseases, including diabetic retinopathy, metastasis, and tumor formulation, various research institutions and organizations are heavily investing in research activities for the development of novel therapies and enhancing their efficacy. For instance, the Greater Houston Retina Research is in the phase four of their interventional study of long-term efficacy and safety of intravitreal aflibercept injections for treating diabetic retinopathy for subjects who completed the 2-year PANORAMA trial. The subjects will be evaluated for efficacy with the aid of best corrected visual acuity by using spectral domain optical coherence tomography (SD-OCT), fluorescein angiography (FA), optical coherence tomography angiography (OCT-A), FP, 4-meter ETDRS protocol with normal-luminance, and Humphrey Visual Field (HVF) through 112 weeks.

In Vitro Angiogenesis Accounts for Significant Market Share

The in vitro application accounts for a significant share of the market owing to the increasing utilization of the device for the measurement of proteins among other substances available in tissues and biological fluids, such as serum, blood, and urine. For instance, the CHEMICON In Vitro Angiogenesis Kit provides a system for evaluating tube formation by endothelial cells in a 96-well format. This kit represents a simple model of angiogenesis where the inhibition or induction of tube formation by exogenous signals is monitored easily. The assay can be used for monitoring the extent of tube assembly in different endothelial cells such as bovine capillary endothelial cells and human umbilical vein cells.

Hospitals Expected to Witness Significant Growth Over Forecast Period

The hospital segment is expected to generate significant revenue due to the high demand for angiogenesis inhibitors and stimulators owing to increased awareness and rising incidences of patients with uncontrolled angiogenesis. The increased spending of hospitals on angiogenesis inhibitor and stimulator therapies can also be attributed to the growing requirement for innovative therapies due to the expansion of the medical tourism industry. The increasing prevalence of age-related macular degeneration is further encouraging hospitals to invest in angiogenesis inhibitors as they are critical for the treatment and prevention of the disease. According to an article published in Journal Cureus, in September 2022, it was estimated that 200 million people suffer from AMD. This number is projected to increase to roughly 300 million by 2040.

Future Market Scenario (2024 - 2031F)

Takeda Pharmaceuticals, one of the leading research and development driven pharmaceutical companies, is involved in an interventional study that aims to evaluate the effect of lxazomib in combination with dexamethasone and lenalidomide on the progression of multiple myeloma in two years in patients who had previously received a bortezomib-based induction regimen. The study is expected to conclude in November 2026.

The National Cancer Institute of Naples is in the phase 4 of a study that is being conducted to explore the role of biological and clinical factors in patients with ovarian cancer that are receiving paclitaxel and carboplatin with bevacizumab. The study is expected to conclude in December 2024.

Key Players Landscape and Outlook

Key participants in the angiogenesis inhibitors and stimulators market include F. Hoffmann-La Roche, Ltd., Bristol-Myers Squibb Company, Eyetech, Inc., Bayer AG, and Takeda Pharmaceutical Company Ltd. The market is witnessing significant growth owing to rising investments in healthcare infrastructure, advancements in precision medicine, and increasing prevalence of cancer.

Hoffmann-La Roche, a multinational healthcare and pharmaceutical company, is conducting a stage four clinical trial in an interventional study of Bevacizumab in patients suffering from metastatic or advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. The study is expected to conclude in June 2025.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Angiogenesis Inhibitors and Stimulators Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Product
    • 4.2.1. Angiogenesis Tube Formation Assays
    • 4.2.2. Microfluidic
    • 4.2.3. Endothelial Adhesion
    • 4.2.4. Invasion and Migration Assays
  • 4.3. By Application
    • 4.3.1. In Vitro Angiogenesis
    • 4.3.2. In Vivo Angiogenesis
  • 4.4. End-user
    • 4.4.1. Hospitals
    • 4.4.2. Clinics
    • 4.4.3. Others
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. South America
    • 4.5.3. Europe
    • 4.5.4. Asia-Pacific
    • 4.5.5. Middle East & Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Angiogenesis Inhibitors and Stimulators Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Product
      • 5.1.2.1. Angiogenesis Tube Formation Assays
      • 5.1.2.2. Microfluidic
      • 5.1.2.3. Endothelial Adhesion
      • 5.1.2.4. Invasion and Migration Assays
    • 5.1.3. By Application
      • 5.1.3.1. In Vitro Angiogenesis
      • 5.1.3.2. In Vivo Angiogenesis
    • 5.1.4. By End-user
      • 5.1.4.1. Hospitals
      • 5.1.4.2. Clinics
      • 5.1.4.3. Others
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
      • 5.1.5.1.1. By Value
      • 5.1.5.1.2. By Volume
      • 5.1.5.2. By Product
      • 5.1.5.2.1. Angiogenesis Tube Formation Assays
      • 5.1.5.2.2. Microfluidic
      • 5.1.5.2.3. Endothelial Adhesion
      • 5.1.5.2.4. Invasion and Migration Assays
      • 5.1.5.3. By Application
      • 5.1.5.3.1. In Vitro Angiogenesis
      • 5.1.5.3.2. In Vivo Angiogenesis
      • 5.1.5.4. End-user
      • 5.1.5.4.1. Hospitals
      • 5.1.5.4.2. Clinics
      • 5.1.5.4.3. Others
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Product
  • 6.2. By Application
  • 6.3. By End-user
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Patent Landscape
  • 9.2. Regulatory Approvals
  • 9.3. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Pfizer, Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Novartis AG
  • 13.3. Abbott Laboratories
  • 13.4. F. Hoffmann-La Roche, Ltd.
  • 13.5. Johns Hopkins Medicine
  • 13.6. Bristol-Myers Squibb Company
  • 13.7. Eyetech, Inc.
  • 13.8. Bayer AG
  • 13.9. Takeda Pharmaceutical Company Ltd.
  • 13.10. Sun Pharmaceutical Industries Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 4. Global Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 5. Global Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global Angiogenesis Inhibitors and Stimulators Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 10. North America Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 11. North America Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 12. North America Angiogenesis Inhibitors and Stimulators Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 16. United States Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 17. United States Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 18. Canada Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 21. Canada Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 22. Canada Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 23. Mexico Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 26. Mexico Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 27. Mexico Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 28. Europe Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 31. Europe Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 32. Europe Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Angiogenesis Inhibitors and Stimulators Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 37. Germany Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 38. Germany Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 39. France Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 42. France Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 43. France Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 44. Italy Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 47. Italy Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 48. Italy Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 49. United Kingdom Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 52. United Kingdom Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 53. United Kingdom Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 54. Russia Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 57. Russia Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 58. Russia Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 59. Netherlands Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 62. Netherlands Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 63. Netherlands Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 64. Spain Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 67. Spain Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 68. Spain Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 69. Turkey Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 72. Turkey Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 73. Turkey Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 74. Poland Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 77. Poland Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 78. Poland Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 79. South America Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 82. South America Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 83. South America Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 84. South America Angiogenesis Inhibitors and Stimulators Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 88. Brazil Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 89. Brazil Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 90. Argentina Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 93. Argentina Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 94. Argentina Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 95. Asia-Pacific Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 98. Asia-Pacific Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 99. Asia-Pacific Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 100. Asia-Pacific Angiogenesis Inhibitors and Stimulators Market Share (%), By Country, 2017-2031F
  • Figure 101. India Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 104. India Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 105. India Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 106. China Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 109. China Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 110. China Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 111. Japan Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 114. Japan Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 115. Japan Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 116. Australia Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 119. Australia Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 120. Australia Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 121. Vietnam Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 124. Vietnam Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 125. Vietnam Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 126. South Korea Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 129. South Korea Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 130. South Korea Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 131. Indonesia Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 134. Indonesia Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 135. Indonesia Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 136. Philippines Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 139. Philippines Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 140. Philippines Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 141. Middle East & Africa Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 144. Middle East & Africa Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 145. Middle East & Africa Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 146. Middle East & Africa Angiogenesis Inhibitors and Stimulators Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 150. Saudi Arabia Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 151. Saudi Arabia Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 152. UAE Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 155. UAE Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 156. UAE Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 157. South Africa Angiogenesis Inhibitors and Stimulators Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Angiogenesis Inhibitors and Stimulators Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Angiogenesis Inhibitors and Stimulators Market Share (%), By Product, 2017-2031F
  • Figure 160. South Africa Angiogenesis Inhibitors and Stimulators Market Share (%), By Application, 2017-2031F
  • Figure 161. South Africa Angiogenesis Inhibitors and Stimulators Market Share (%), By End-user, 2017-2031F
  • Figure 162. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023